NASDAQ · OTLK
Healthcare · Biotechnology
$0.46
Up+$0.02 (+5.25%)
Updated Nov 10, 2026, 8:47 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OTLK
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 9, 2026
OTLK closed at $0.46 after 21 trading sessions, down 21.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | $0.4364 | $0.4661 | $0.435 | $0.4593 | 1.96M |
| Nov 6, 2026 | $0.421 | $0.4398 | $0.42 | $0.4364 | 1.64M |
| Nov 5, 2026 | $0.46 | $0.4672 | $0.4086 | $0.4391 | 4.16M |
| Nov 4, 2026 | $0.4595 | $0.4779 | $0.4447 | $0.4621 | 2.72M |
| Nov 3, 2026 | $0.4625 | $0.4798 | $0.452 | $0.46 | 2.52M |
| Nov 2, 2026 | $0.4691 | $0.4817 | $0.4457 | $0.4692 | 2.28M |
| Oct 30, 2026 | $0.49 | $0.493 | $0.45 | $0.4681 | 4.79M |
| Oct 29, 2026 | $0.5292 | $0.5388 | $0.48 | $0.4935 | 7.06M |
| Oct 28, 2026 | $0.53 | $0.5469 | $0.5212 | $0.5449 | 2.14M |
| Oct 27, 2026 | $0.5222 | $0.5413 | $0.505 | $0.5298 | 3.26M |
| Oct 26, 2026 | $0.512 | $0.5292 | $0.4872 | $0.5133 | 2.53M |
| Oct 23, 2026 | $0.5571 | $0.56 | $0.5113 | $0.5193 | 3.08M |
| Oct 22, 2026 | $0.5627 | $0.5999 | $0.5444 | $0.5635 | 4.4M |
| Oct 21, 2026 | $0.529 | $0.57 | $0.5269 | $0.5613 | 3M |
| Oct 20, 2026 | $0.50 | $0.60 | $0.50 | $0.52 | 3.31M |
| Oct 19, 2026 | $0.4903 | $0.5217 | $0.4809 | $0.493 | 2.63M |
| Oct 16, 2026 | $0.52 | $0.5326 | $0.485 | $0.4882 | 3.12M |
| Oct 15, 2026 | $0.4881 | $0.5099 | $0.4379 | $0.50 | 5.35M |
| Oct 14, 2026 | $0.5571 | $0.5651 | $0.47 | $0.4702 | 9.64M |
| Oct 13, 2026 | $0.5788 | $0.5812 | $0.551 | $0.5638 | 3.25M |
| Oct 12, 2026 | $0.599 | $0.60 | $0.57 | $0.5851 | 2.31M |
The latest Smart Investors Daily articles mentioning OTLK.
Company
Market Activity
Research & News
OTLK research
Company profile and research snapshot.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Ascendiant Capital | Buy | — |
| Aug 14, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | BTIG | Buy | — |
| Jul 27, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 11, 2026 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A
Benzinga · Feb 19, 2026
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service
Benzinga · Feb 18, 2026
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $0.5 price target.
Benzinga · Feb 17, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OTLK.
